Gilead (GILD) +11.3% after saying over the weekend that a combination of its hepatitis C...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead (GILD) +11.3% after saying over the weekend that a combination of its hepatitis C therapies sofosbuvir and GS-5885, along with the antiviral drug ribavirin, cleared the virus in all 25 patients in a Phase II study. "This is starting to look like a home-run," says RBC analyst Michael Yee. Gilead's excellent results add to very good Phase II data from Merck and Abbott Labs. (PR)